Multiple Sclerosis: Close To Being Conquered

The development of a plethora of new medicines for multiple sclerosis over the past 10 years is truly remarkable. As well as the dozen or so agents now available to treat relapsing MS, the first potential product for the poorly treated condition, primary progressive MS, is nearing the market.

If you question neuroscientists, they will tell you we are nearing a time when it might be possible to reverse neuronal damage and promote the regrowth of myelin sheaths around nerve axons, perhaps stopping the underlying cause of multiple sclerosis in its tracks.

The insulating sheaths of neurons are critical to their function, and if they are damaged, communication between nerves slows down...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.